These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36533572)

  • 1. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
    Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
    Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study.
    Dai L; Gao T; Guo R; Chen Y; Wang J; Zhou S; Tang Y; Chen D; Huang S
    Neoplasia; 2024 Oct; 56():101029. PubMed ID: 39024777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of pyrotinib and radiotherapy
    Chen J; Zhang H; Zhou J; Wu Z; Wu X; Zhang S; Jiang Z; Wang T
    Ann Transl Med; 2022 Nov; 10(22):1228. PubMed ID: 36544628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
    Liang X; Gui X; Yan Y; Di L; Liu X; Li H; Song G
    Oncologist; 2024 Feb; 29(2):e198-e205. PubMed ID: 37589217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.
    Yang Z; Meng J; Mei X; Mo M; Xiao Q; Han X; Zhang L; Shi W; Chen X; Ma J; Palmer J; Shao Z; Zhang Z; Yu X; Guo X
    JAMA Oncol; 2024 Mar; 10(3):335-341. PubMed ID: 38175627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.
    Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
    Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
    Shawky H; Tawfik H
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
    Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
    Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
    He M; Liu J; Wang Z; Ma F; Wang J; Zhang P; Li Q; Yuan P; Luo Y; Fan Y; Mo H; Lan B; Li Q; Xu B
    Breast; 2023 Dec; 72():103581. PubMed ID: 37742492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases.
    Huang J; Zhu W; Duan Q; Zhu C; Shi X; Zhao H; Cai P; Li D
    Breast Cancer (Dove Med Press); 2023; 15():841-853. PubMed ID: 38020051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
    Li X; Wu S; Zhang L; Zhu J; Xu B
    Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
    Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
    Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.
    Huang J; Sun S; Tan Q; Zheng F; Zhou D; Man X; Hu Y; Li W; Song L; Zhang B; Xu L; Wang X; Xie X; Li H
    Clin Breast Cancer; 2024 Aug; 24(6):e509-e518.e1. PubMed ID: 38729821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
    Yuan Y; Liu X; Cai Y; Li W
    PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.